Applied DNA Sciences Files 8-K

TL;DR

APDN filed an 8-K on Nov 4, 2025, for a material agreement and financials. Details TBD.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on November 4, 2025, reporting an entry into a material definitive agreement and filing financial statements and exhibits. The filing does not specify the details of the agreement or the financial statements.

Why It Matters

This filing indicates a significant event or transaction for Applied DNA Sciences, Inc., requiring disclosure to investors.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the lack of specific details about the material agreement and financial statements introduces uncertainty.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• November 4, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-36745 (identifier) — Commission File Number
• 59-2262718 (identifier) — IRS Employer Identification No.
• 50 Health Sciences Drive (address) — Business and mailing address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value BNBX The Nasdaq Stock Mar
• $8,157,932 — th an aggregate offering price of up to $8,157,932 (the " Shares ") through the Agent. Th
• $50,000 — its legal counsel up to an aggregate of $50,000 for the commencement of this offering p
• $5,000 — nal amount for its counsel's fees up to $5,000 in connection with the filing of a Form
• $2,500 — t or an amendment to the Agreement, and $2,500 in connection with the filing of a Form
• $175,000 — of the Agreement, will be approximately $175,000. After commencement of the offering, fr

Filing Documents

• tm2529307d1_8k.htm (8-K) — 32KB
• tm2529307d1_ex1-1.htm (EX-1.1) — 218KB
• tm2529307d1_ex5-1.htm (EX-5.1) — 10KB
• tm2529307d1_ex99-1.htm (EX-99.1) — 58KB
• tm2529927d2_ex5-1img002.jpg (GRAPHIC) — 4KB
• tm2529927d2_ex5-1img003.jpg (GRAPHIC) — 4KB
• tm2529927d2_ex99-1img001.jpg (GRAPHIC) — 5KB
• 0001104659-25-105945.txt ( ) — 571KB
• bnbx-20251104.xsd (EX-101.SCH) — 3KB
• bnbx-20251104_lab.xml (EX-101.LAB) — 33KB
• bnbx-20251104_pre.xml (EX-101.PRE) — 22KB
• tm2529307d1_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement On November 4, 2025, Applied DNA Sciences, Inc. (the " Company ") entered into an At The Market Offering Agreement (the " Agreement ") with Lucid Capital Markets, LLC, as sales agent (the " Agent "), pursuant to which the Company may, from time to time, offer and sell shares of its common stock, par value $0.001 per share, with an aggregate offering price of up to $8,157,932 (the " Shares ") through the Agent. The offer and sale of the Shares made pursuant to the Agreement, if any, will be made under the Company's effective "shelf" registration statement on Form S-3 (File No. 333-272267) filed May 30, 2023, the base prospectus contained therein, and a prospectus supplement related to the offering of the Shares dated November 4, 2025. Under the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an "at the market offering" as defined in Rule 415 under the Securities Act of 1933, as amended. based upon the Company's instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents and certificates in connection with sales of the Shares. The Company will pay the Agent in cash, upon each sale of Shares sold pursuant to the Agreement, a fixed commission rate equal to 3.0% of the gross sales price of the common stock issued and sold by the Company through the Agent. If the Company sells Shares to the Agent as principal, the Company will enter into a separate terms agreement with the Agent setting for

Financial Statements and Exhibits

Financial Statements and Exhibits The following exhibits are being filed herewith: (d) Exhibits Exhibit No. Document 1.1 At The Market Offering Agreement, dated November 4, 2025, by and between Applied DNA Sciences, Inc. and Lucid Capital Markets, LLC 5.1 Opinion of McDermott Will & Schulte LLP 23.1 Consent of McDermott Will & Schulte LLP (included in Exhibit 5.1) 99.1 Form of Consulting Agreement, dated October 1, 2025, by and between Applied DNA Sciences, Inc. and Patrick Horsman 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 4, 2025 APPLIED DNA SCIENCES, INC. By: /s/ Beth Jantzen Name: Beth Jantzen Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR